Cryoablation and immunotherapy: an overview of evidence on its synergy von Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., Gómez, F. M.

Volltext

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/II... von Borgers, J S W, Burgers, F H, Terveer, E M, van Leerdam, M E, Korse, C M, Kessels, R, Flohil, C C, Blank, C U, Schumacher, T N, van Dijk, M, Henderickx, J G E, Keller, J J, Verspaget, H W, Kuijper, E J, Haanen, J B A G

Volltext

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers von Trebeschi, S., Drago, S.G., Birkbak, N.J., Kurilova, I., Cǎlin, A.M., Delli Pizzi, A., Lalezari, F., Lambregts, D.M.J., Rohaan, M.W., Parmar, C., Rozeman, E.A., Hartemink, K.J., Swanton, C., Haanen, J B A G, Blank, C.U., Smit, E.F., Beets-Tan, R.G.H., Aerts, H.J.W.L

Volltext

Clinical Pharmacokinetics of Vemurafenib in BRAF‐Mutated Melanoma Patients von Nijenhuis, C. M., Huitema, A. D. R., Blank, C., Haanen, J. B. A. G., Thienen, J. V., Rosing, H., Schellens, J. H. M., Beijnen, J. H.

Volltext

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer von Geukes Foppen, M.H., Donia, M., Svane, I.M., Haanen, J.B.A.G.

Volltext

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry von De Groot, S, Sleijfer, S, Redekop, W K, Oosterwijk, E, Haanen, J B A G, Kiemeney, L A L M, Uyl-de Groot, C A

Volltext

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients von HAANEN, J. B. A. G, BAARS, A, PINEDO, H. M, VAN DEN EERTWEGH, A. J. M, GOMEZ, R, WEDER, P, SMITS, M, DE GRUIJL, T. D, VON BLOMBERG, B. M. E, BLOEMENA, E, SCHEPER, R. J, VAN HAM, S. M

Volltext

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Haanen, J.B.A.G., Carbonnel, F., Robert, C., Kerr, K.M., Peters, S., Larkin, J., Jordan, K.

Volltext

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients von Groenland, Stefanie L., Janssen, J. M., Nijenhuis, C. M., de Vries, N., Rosing, H., Wilgenhof, S., van Thienen, J. V., Haanen, J. B. A. G., Blank, C. U., Beijnen, J. H., Huitema, A. D. R., Steeghs, N.

Volltext

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study von Long, G.V., Flaherty, K.T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B.A.G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M.A., Lane, S.R., Legos, J.J., Mookerjee, B., Grob, J.-J.

Volltext

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer von van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G

Volltext

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma von Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Volltext

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up von Haanen, J B A G, Carbonnel, F, Robert, C, Kerr, K M, Peters, S, Larkin, J, Jordan, K

Volltext

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials von Versluis, J.M., Menzies, A.M., Sikorska, K., Rozeman, E.A., Saw, R.P.M., van Houdt, W.J., Eriksson, H., Klop, W.M.C., Ch’ng, S., van Thienen, J.V., Mallo, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L.G., van der Wal, A., Bruining, A., van de Wiel, B.A., Scolyer, R.A., Haanen, J.B.A.G., Schumacher, T.N., van Akkooi, A.C.J., Long, G.V., Blank, C.U.

Volltext

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? von Nijenhuis, C.M, Haanen, J.B.A.G, Schellens, J.H.M, Beijnen, J.H

Volltext

Transposon leads to contamination of clinical pDNA vaccine von van der Heijden, I, Gomez-Eerland, R, van den Berg, J.H, Oosterhuis, K, Schumacher, T.N, Haanen, J.B.A.G, Beijnen, J.H, Nuijen, B

Volltext

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis von Martín-Lluesma, S., Svane, I.M., Dafni, U., Vervita, K., Karlis, D., Dimopoulou, G., Tsourti, Z., Rohaan, M.W., Haanen, J.B.A.G., Coukos, G.

Volltext

DNA tattoo vaccination: Effect on plasmid purity and transfection efficiency of different topoisoforms von Quaak, S.G.L., den Berg, J.H. van, Oosterhuis, K., Beijnen, J.H., Haanen, J.B.A.G., Nuijen, B.

Volltext

GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial von Quaak, S.G.L., van den Berg, J.H., Toebes, M., Schumacher, T.N.M., Haanen, J.B.A.G., Beijnen, J.H., Nuijen, B.

Volltext

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours von Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N

Volltext